Based on previous research, the RCC therapeutic target proteins taken for the study were VEGF (vascular endothelial growth factor), HGF (hepatocyte growth factor), PDGF (platelet-derived growth factor), GDNF (glial cell derived neurotrophic factor), and mTOR (mammalian target of rapamycin) (24–27). Here, MTOR is linked to renal cell carcinoma.